Reference health
Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents
2 of 83 checkable references need attention · checked 2026-07-23
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1161/circ.122.suppl_21.A12420
does not resolve to a known work10.1161/circ.126.suppl_21.A11395
The 81 checked references that resolve
resolves10.1056/NEJMoa1306638
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
resolves10.1186/1477-9560-11-21
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
resolves10.1161/CIRCULATIONAHA.113.004450
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
resolves10.1016/S0140-6736(13)62343-0
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
resolves10.1111/jth.12485
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis
resolves10.1182/blood-2014-03-563577
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
resolves10.1160/TH14-11-0954
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation
resolves10.1161/CIRCULATIONAHA.114.012061
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
resolves10.1016/j.jacc.2013.03.020
Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation
resolves10.1016/j.amjmed.2014.01.031
Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation
resolves10.1016/j.jacc.2014.02.549
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
resolves10.1161/CIRCULATIONAHA.113.002332
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
resolves10.1093/europace/euv233
Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
resolves10.1093/europace/euv309
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
resolves10.1016/j.jacc.2015.01.049
Practical Management of Anticoagulation in Patients With Atrial Fibrillation
resolves10.1160/TH15-03-0222
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
resolves10.1007/s40256-013-0055-y
Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
resolves10.4137/CCRep.S27992
Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants
resolves10.1182/blood-2011-11-393587
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
resolves10.1111/bjh.13236
Intermittent haemodialysis and continuous veno‐venous dialysis are effective in mitigating major bleeding due to dabigatran
resolves10.1007/s12185-015-1739-7
Management of dabigatran-induced bleeding with continuous venovenous hemodialysis
resolves10.1160/TH14-06-0547
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis
resolves10.1002/jcph.628
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis
resolves10.1160/TH09-11-0758
Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
resolves10.1111/j.1538-7836.2012.04859.x
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
resolves10.1097/ALN.0b013e318238c036
Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model
resolves10.1111/j.1538-7836.2012.04863.x
Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate
resolves10.1160/TH12-12-0907
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates
resolves10.1016/j.ijcard.2013.07.152
Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis
resolves10.1161/STROKEAHA.112.675231
Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With Rivaroxaban
resolves10.1160/TH14-08-0712
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab
resolves10.1161/CIRCULATIONAHA.111.029017
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
resolves10.1111/jth.12599
Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
resolves10.1161/CIRCULATIONAHA.114.013445
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
resolves10.1160/TH12-03-0179
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
resolves10.1371/journal.pone.0078696
Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood
resolves10.1160/TH11-09-0668
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents
resolves10.1160/TH13-07-0607
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban
resolves10.1177/1076029613494468
Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban
resolves10.1016/j.thromres.2014.01.017
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro
resolves10.1253/circj.CJ-14-0909
Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates
resolves10.1007/s11239-015-1167-9
Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents
resolves10.1097/MBC.0b013e32834f1b0c
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
resolves10.1111/jth.12236
In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban
resolves10.2165/11318170-000000000-00000
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
resolves10.1161/CIRCULATIONAHA.113.002283
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding
resolves10.1182/blood-2012-02-408930
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry
resolves10.1160/TH11-01-0052
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists
resolves10.1046/j.1365-2516.2002.00532.x
Safety of factor VIII inhibitor bypass activity (FEIBA<sup>®</sup>): 10‐year compilation of thrombotic adverse events
resolves10.1111/jth.13227
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH
resolves10.1182/blood-2012-11-468207
A specific antidote for dabigatran: functional and structural characterization
resolves10.1160/TH14-12-1080
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran
resolves10.1177/0091270011413894
Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics
resolves10.1182/blood.V120.21.3418.3418
In Vitro Characterization, Pharmacokinetics and Reversal of Supratherapeutic Doses of Dabigatran-Induced Bleeding in Rats by a Specific Antibody Fragment Antidote to Dabigatran
resolves10.1016/S0735-1097(11)61130-3
DABIGATRAN ANTICOAGULANT ACTIVITY IS NEUTRALIZED BY AN ANTIBODY SELECTIVE TO DABIGATRAN IN IN VITRO AND IN VIVO MODELS
resolves10.1161/circ.130.suppl_2.18544
Abstract 18544: Bloods Loss in Dabigatran Anticoagulated Pigs With Polytrauma is Significantly Reduced by Early Therapy With Activated and Non-activated Prothrombin Complex Concentrates
resolves10.1182/blood.V124.21.344.344
Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects
resolves10.1016/S0140-6736(15)60732-2
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
resolves10.1038/nm.3102
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
resolves10.1182/blood.V124.21.4269.4269
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors
resolves10.3109/08830185.2014.938325
Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights
resolves10.1093/eurheartj/ehr335
Takayasu's arteritis involving the pulmonary arteries: evaluation by quantitative dual-energy computed tomographic pulmonary angiography
resolves10.1182/blood.V122.21.3636.3636
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors
resolves10.1161/circ.128.suppl_22.A18809
Abstract 18809: PER977: A Synthetic Small Molecule Which Reverses Over-Dosage and Bleeding by the New Oral Anticoagulants
resolves10.1016/j.ahj.2015.03.010
Novel oral anticoagulants and reversal agents: Considerations for clinical development
The 2 references without a DOI — listed, not checked
no DOI — not checkedCrowther M, Kitt M, Lorenz T. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost. 2013; 11: 30.
no DOI — not checkedLaulicht B, Bakhru S, Jiang X. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. J Thromb Haemost. 2013;11:75.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1161/circulationaha.116.021831"><img src="https://citestamp.com/citestamped/10.1161/circulationaha.116.021831/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1161/circulationaha.116.021831)